HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Follow-Up Questions
Hillevax Inc의 CEO는 누구입니까?
Dr. Robert Hershberg은 2020부터 회사에 합류한 Hillevax Inc의 Chairman of the Board입니다.
HLVX 주식의 가격 성능은 어떻습니까?
HLVX의 현재 가격은 $2.09이며, 전 거래일에 decreased 0% 하였습니다.
Hillevax Inc의 주요 사업 주제나 업종은 무엇입니까?
Hillevax Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Hillevax Inc의 시가총액은 얼마입니까?
Hillevax Inc의 현재 시가총액은 $104.7M입니다
Hillevax Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 Hillevax Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다
